Navigation Links
Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
Date:10/1/2011

LAS VEGAS, Oct. 1, 2011 /PRNewswire/ -- This information is being released by SCM:

Dr. Arthur Reingold, witness for the defense in the second hepatitis C trial in Nevada, was called to the stand today offering expert testimony as an epidemiologist. During questioning by the defense, Dr. Reingold testified transference of the deadly virus hepatitis C could have occurred from a lack of hand washing, ungloved hands, bite blocks, biopsy equipment, gowns and aprons, and that cross contamination of bacteria may have occurred on a daily basis. 

(Photo:  http://photos.prnewswire.com/prnh/20111001/LA78785)

When cross examined by lead trial attorney for the plaintiffs, Robert Eglet, Dr. Reingold responded to questions about his testimony concerning transmission of hepatitis C at the Endoscopy Center of Southern Nevada.

"You can not state with certainty or to any reasonable degree of medical probability or have any evidence that the GI techs or any specific person was not wearing gloves, or that ungloved hands were the cause of transmission of the hepatitis C virus, or that the CRNAs were not washing their hands or wearing gowns or aprons that may have served as the source of the transmission of hepatitis C to Anne Arnold?" said Eglet. "No," stated Reingold. So you are not saying that hepatitis C on an apron somehow found its way into the bloodstream of Anne Arnold, Correct?" said Eglet. "Yes," stated Reingold.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

This is the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected. In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs. 


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Lehigh University leads Department of Defense MURI grant for atomic-scale interphase research
4. Winners of inaugural defense fellowships to further research at NTU
5. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
6. Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defenses Net Zero Energy Initiative
7. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
8. TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs
9. NJIT physicist sees terahertz imaging as ultimate defense against terrorism
10. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
11. UCLA gets $5.5 million from Defense agency to create new rotating microscale motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017 ... Biotech Venture Fund (MBVF), today announced positive results of ... the standard drug therapy regimen in patients with multidrug-resistant ... drug discovered by scientists at Sequella, Inc. ( ... Health. A total of 140 patients ...
(Date:3/24/2017)... March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the ... China , today announced that its board of directors ... of the plan from March 27, 2017 to March 27, 2018. The ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/24/2017)... March 24, 2017   Sienna Biopharmaceuticals, Inc. , ... today announced that Richard Peterson will join ... Peterson, who brings more than two decades ... , who is retiring at the end of April ... capacity. Peterson joins Sienna from Novan, Inc., where he ...
(Date:3/23/2017)... MA (PRWEB) , ... March 23, 2017 , ... ... “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which ... disc polymer exhibits properties to gently absorb compressive forces and return to its ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
Breaking Biology News(10 mins):